Jason A. Amello
Net Worth
Last updated:
What is Jason A. Amello net worth?
The estimated net worth of Mr. Jason A. Amello is at least $5,234,865 as of 28 Feb 2020. He owns shares worth $442,605 as insider and has received compensation worth at least $4,792,260 in Akebia Therapeutics, Inc..
What is the salary of Jason A. Amello?
Mr. Jason A. Amello salary is $435,660 per year as Executive Officer in Akebia Therapeutics, Inc..
How old is Jason A. Amello?
Mr. Jason A. Amello is 57 years old, born in 1968.
What stocks does Jason A. Amello currently own?
As insider, Mr. Jason A. Amello owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | Executive Officer | 144,642 | $3.06 | $442,605 |
What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Jason A. Amello insider trading
Akebia Therapeutics, Inc.
Mr. Jason A. Amello has made only one insider trade between 2014-2020, according to the Form 4 filled with the SEC. He sold 6,976 units of AKBA stock on 28 Feb 2020.
As of 28 Feb 2020 he still owns at least 144,642 units of AKBA stock.
Akebia Therapeutics key executives
Akebia Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Steven Keith Burke (64) Senior Vice President of R&D and Chief Medical Officer
- Mr. David A. Spellman (48) Senior Vice President, Chief Financial Officer & Treasurer
- Mr. Dell Faulkingham (52) Senior Vice President & Chief Commercial Officer
- Mr. Jason A. Amello (57) Executive Officer
- Mr. John P. Butler MBA (61) Chief Executive Officer, Pres & Director
- Mr. Michel Dahan (46) Senior Vice President & Chief Operating Officer